Byungwoo Ryu, PhD
Assistant Professor
Boston University School of Medicine
Dept of Dermatology

PhD, Oregon State University
MS, Chonbuk National University



Dr. Ryu joined the Department of Dermatology at the Boston University of School of Medicine as an assistant Professor in 2011. He received his Ph.D. degree from Oregon State University in Molecular Toxicology. Dr. Ryu completed his postdoctoral fellowships at the National Cancer Institute in Bethesda, Maryland and Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine, Baltimore, Maryland. Dr. Ryu served as an assistant member of the Nevada Cancer Institute at Las Vegas, Nevada and clinical assistant professor of medicine at the University of Nevada School of Medicine at Reno, Nevada. Dr. Ryu is a recipient of Howard Temin Award, career development award (K01), from the National Cancer Institute.

Dr. Ryu’s research interest is to determine the molecular events that dictate melanoma tumorigenicity and malignant progression. It is likely that identification of such molecular pathways will allow us to identify clinically useful biomarkers as well as potential therapeutic targets against this lethal form of skin cancer.

Biomarkers for melanoma progression: Dr. Ryu’s laboratory currently focuses on discovery of molecular biomarkers that can be used for patient stratification and personalized therapy. His laboratory uses genomic and molecular profiling techniques on tissue and blood samples from melanoma patients to find patterns of molecular signatures and correlate them with clinical outcomes.

Therapeutic targeting of metastasis-initiating cells (MICs): Despite recent progress, the molecular mechanisms of tumor metastasis remain unclear. Isolation and dissection of the MICs, subpopulation of tumor cells including circulating cancer cells in patient’s blood, will shed light on the molecular events of metastasis progression. Dr. Ryu’s laboratory focuses on the genetic and epigenetic characterization of the MICs as well as developing therapeutic and preventive strategies of cancer metastasis by targeting the MICs.


Epigenetic detection and chemoprevention of skin cancer
10/01/2015 - 06/30/2016 (PI)
Johns Hopkins University V Foundation

Melanoma Assays Based on NRP-2
05/01/2010 - 09/30/2015 (Co-PI)
PI: Rhoda Alani, MD
Laboratory Corporation of America

Development of Novel Markers for Melanoma Progression
10/01/2011 - 06/30/2012 (PI)
NIH/National Institutes of Health
7K01CA113779-07




Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Hwang S, Kim HE, Min M, Raghunathan R, Panova IP, Munshi R, Ryu B. Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma. J Invest Dermatol. 2015 Sep; 135(9):2283-91.View Related Profiles. PMID: 25910030; PMCID: PMC4537358; DOI: 10.1038/jid.2015.160;.
  2. Rossi M, Tuck J, Kim OJ, Panova I, Symanowski JT, Mahalingam M, Riker AI, Alani RM, Ryu B. Neuropilin-2 gene expression correlates with malignant progression in cutaneous melanoma. Br J Dermatol. 2014 Aug; 171(2):403-8.View Related Profiles. PMID: 24359286; DOI: 10.1111/bjd.12801;.
  3. Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, Wang Y, Leslie NR, Xu GX, Widlund HR, Ryu B, Alani RM, Dutton-Regester K, Goding CR, Hayward NK, Wei W, Cui R. MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell. 2013 Aug 22; 51(4):409-22.View Related Profiles. PMID: 23973372; PMCID: PMC3792490; DOI: 10.1016/j.molcel.2013.08.010;.
  4. Ryu B, Hwang S, Alani RM. MicroRNAs as an emerging target for melanoma therapy. J Invest Dermatol. 2013 May; 133(5):1137-9.View Related Profiles. PMID: 23594536; DOI: 10.1038/jid.2012.505;.
  5. Yan G, Eller MS, Elm C, Larocca CA, Ryu B, Panova IP, Dancy BM, Bowers EM, Meyers D, Lareau L, Cole PA, Taverna SD, Alani RM. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J Invest Dermatol. 2013 Oct; 133(10):2444-52.View Related Profiles. PMID: 23698071; DOI: 10.1038/jid.2013.187;.
  6. Liu F, Cao J, Wu J, Sullivan K, Shen J, Ryu B, Xu Z, Wei W, Cui R. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol. 2013 Aug; 133(8):2041-9.View Related Profiles. PMID: 23344460; DOI: 10.1038/jid.2013.32;.
  7. Ryu B, Moriarty WF, Stine MJ, DeLuca A, Kim DS, Meeker AK, Grills LD, Switzer RA, Eller MS, Alani RM. Global analysis of BRAFV600E target genes in human melanocytes identifies matrix metalloproteinase-1 as a critical mediator of melanoma growth. J Invest Dermatol. 2011 Jul; 131(7):1579-83.View Related Profiles. PMID: 21451543; PMCID: PMC3116059; DOI: 10.1038/jid.2011.65;.
  8. Stine MJ, Wang CJ, Moriarty WF, Ryu B, Cheong R, Westra WH, Levchenko A, Alani RM. Integration of genotypic and phenotypic screening reveals molecular mediators of melanoma-stromal interaction. Cancer Res. 2011 Apr 1; 71(7):2433-44.View Related Profiles. PMID: 21324919; PMCID: PMC3070809; DOI: 10.1158/0008-5472.CAN-10-1875;.
  9. Kim HE, Symanowski JT, Samlowski EE, Gonzales J, Ryu B. Quantitative measurement of circulating lymphoid-specific helicase (HELLS) gene transcript: a potential serum biomarker for melanoma metastasis. Pigment Cell Melanoma Res. 2010 Dec; 23(6):845-8. PMID: 20727106; PMCID: PMC3192016; DOI: 10.1111/j.1755-148X.2010.00753.x;.
  10. Cummings SD, Ryu B, Samuels MA, Yu X, Meeker AK, Healey MA, Alani RM. Id1 delays senescence of primary human melanocytes. Mol Carcinog. 2008 Sep; 47(9):653-9.View Related Profiles. PMID: 18240291; DOI: 10.1002/mc.20422;.
Showing 10 of 30 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 30 publications over 16 distinct years, with a maximum of 5 publications in 2001

YearPublications
19941
19951
19961
20002
20015
20022
20034
20041
20051
20072
20081
20101
20112
20134
20141
20151
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Biomarkers
Epigenetics
Melanoma
Metastasis
Therapeutic target discovery
Tumor-microenvironment
Contact for Mentoring:


609 Albany St (J Bldg)
Boston MA 02118
Google Map


Ryu's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department